Validation of an Allergic Rhinitis Control Test in Teenagers
- Conditions
- Allergic Rhinitis
- Interventions
- Other: Self questionnaire for allergic rhinitis control
- Registration Number
- NCT02818153
- Lead Sponsor
- University Hospital, Montpellier
- Brief Summary
Allergic rhinitis is a common condition that affects adults as well as children and adolescents, often with impaired quality of life. Patients often report a poor level of satisfaction with the effectiveness of their treatment and are always looking for more drug combinations to improve their symptom. Several tools exist for assessing control of allergic rhinitis, but none has been validated in adolescents or in children. A study conducted in 2008, resulted in the validation of a self-administered control test of allergic rhinitsis (ARCT) in patients from 12 years of age. However, this study included only 67 adolescents aged 12 to 17 years old and lacked power.
In this new study,the investigators propose, following exactly the same procedure as the pilot study of 2008, to confirme the validation of unmodified Adult questionnaire in adolescents 12 to 17 years inclusive.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 200
- Patients aged 12 to 17 years old, consulting a practitioner for an allergic rhinitis
- parents formulated their study participation agreement by signing the consent form.
- Patients that are already treated for the actual episode of allergic rhinitis and are satisfied of the treatement.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description questionnaire for allergic rhinitis control Self questionnaire for allergic rhinitis control Teenagers from 12 to 17 years old who complete a Self questionnaire regarding allergic rhinitis control during the consultation and after 15 days
- Primary Outcome Measures
Name Time Method Score of the allergic rhinitis control self questionnaire in teenagers from 12 to 17 years old. 15 days
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University hospital of Montpellier
🇫🇷Montpellier, France